Week of December 13th 2021 | Vol. 10, Issue 49 |
|
|
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
|
|
For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
|
|
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
|
|
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business
Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America
Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
|
|
Hospital system City of Hope is acquiring Cancer Treatment Centers of America to build a national, integrated cancer research and treatment system. Financial details of the acquisition were not disclosed, but Reuters reported the deal was valued at $390 million.
The acquisition of the network of oncology hospitals and outpatient care centers will “advance the missions of both organizations,” they said in a joint press release, and build a research and treatment system to "transform the future of cancer care.” It will also expand City of Hope’s portfolio and contribute not only to its cancer services but also to research and development.
The organizations said the combined entity will be one of the largest cancer research and treatment organizations in the country with one of the largest geographic footprints, serving approximately 115,000 patients each year.
|
|
RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
|
|
Pharma & Biotech
10 transactions
Supplies, Equipment & Services
24 transactions totaling $2,194 million
Healthcare IT & Managed Care
8 transactions totaling $559
Healthcare Facilities & Distributors
12 transactions totaling $561
|
|
Pharma & Biotech
31 transactions totaling $1,316 million
Supplies, Equipment & Services
15 transactions totaling $548 million
Healthcare IT & Managed Care
19 transactions totaling $711 million
Healthcare Facilities & Distributors
4 transactions totaling $90 million
|
|
Pharma & Biotech
16 transactions totaling $8,496 million
Supplies, Equipment & Services
1 transaction totaling $23
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
1 transaction totaling $3 million
|
|
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
|
|
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
|
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
|
|
December 6, 2021 - Fierce Biotech
Coming in just under the wire to cap off a year filled with outsized medtech special purpose acquisition company deals, BenevolentAI has agreed to combine with SPAC Odyssey in what amounts to Europe’s largest-ever SPAC merger.
December 7, 2021 - Fierce Healthcare
Wages for female physicians amount to an estimated $2 million less than compensation for their male counterparts over the course of a simulated 40-year career, a new study finds.
December 8, 2021 - Fierce Biotech
Vivo Capital, Bain Capital and Primavera Capital have come together to place a $200 million-plus bet on lung cancer startup Avistone Pharmaceuticals as it looks to join forces with fellow oncology company Pearl Biotechnology.
December 9, 2021 - Fierce Biotech
Five years into its lofty goal of funding projects to “cure, prevent or manage all disease within our children’s lifetime,” the Chan Zuckerberg Initiative’s Biohub is getting a major boost.
|
|
Events Hosted or Attended by Bourne Partners
Dates TBD - Charlotte, NC
January 10-14, 2022 - San Francisco, CA
|
|
Tanner Pharma is a specialist pharmaceutical services provider headquartered in Charlotte, NC USA with offices in the United Kingdom, Switzerland, Ireland and Brazil. With a focus on improving patient lives by increasing access to medicines around world, the company has developed a portfolio of service offerings that provide international commercialization and patient access through licensing, managed access programs, global access programs and clinical trial services, as well as donation programs through biopharmaceutical and non-profit partnerships. By partnering with Tanner Pharma Group, companies are able to focus on their primary markets while ensuring that patients and clinicians receive the products they need through compliant and controlled channels. Learn more: www.tannerpharma.com.
|
|
Welcome to Bourne, let's talk.
Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.
|
|
|
|
|
|
|
